Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1972 1
1973 2
1977 1
1979 4
1980 4
1981 5
1982 5
1983 6
1984 13
1985 13
1986 10
1987 13
1988 12
1989 7
1990 7
1991 11
1992 17
1993 16
1994 9
1995 15
1996 9
1997 11
1998 4
1999 10
2000 7
2001 2
2002 5
2003 6
2004 7
2005 5
2006 9
2007 7
2008 3
2009 2
2011 1
2018 1
2019 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

260 results

Results by year

Filters applied: . Clear all
Page 1
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.
Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R; Gynecologic Oncology Group. Ozols RF, et al. J Clin Oncol. 2003 Sep 1;21(17):3194-200. doi: 10.1200/JCO.2003.02.153. Epub 2003 Jul 14. J Clin Oncol. 2003. PMID: 12860964 Corrected and republished. Clinical Trial.
Gynecologic cancers.
Boente MP, Schilder R, Ozols RF. Boente MP, et al. Among authors: ozols rf. Cancer Chemother Biol Response Modif. 1997;17:536-61. Cancer Chemother Biol Response Modif. 1997. PMID: 9551230 Review.
Testicular cancer.
Ozols RF, Williams SD. Ozols RF, et al. Curr Probl Cancer. 1989 Sep-Oct;13(5):285-335. doi: 10.1016/0147-0272(89)90020-2. Curr Probl Cancer. 1989. PMID: 2551577 Review.
Ovarian cancer.
Ozols RF, Young RC. Ozols RF, et al. Curr Probl Cancer. 1987 Mar-Apr;11(2):57-122. doi: 10.1016/s0147-0272(87)80004-1. Curr Probl Cancer. 1987. PMID: 3556023 Review.
Optimal dosing with carboplatin.
Ozols RF. Ozols RF. Semin Oncol. 1989 Apr;16(2 Suppl 5):14-8. Semin Oncol. 1989. PMID: 2655094 Review.
The anthracycline antineoplastic drugs.
Young RC, Ozols RF, Myers CE. Young RC, et al. Among authors: ozols rf. N Engl J Med. 1981 Jul 16;305(3):139-53. doi: 10.1056/NEJM198107163050305. N Engl J Med. 1981. PMID: 7017406 Review. No abstract available.
Ovarian cancer: new clinical approaches.
Ozols RF. Ozols RF. Cancer Treat Rev. 1991 Mar;18 Suppl A:77-83. doi: 10.1016/0305-7372(91)90027-w. Cancer Treat Rev. 1991. PMID: 1904312 Review. No abstract available.
Glutathione and drug resistance.
Schröder CP, Godwin AK, O'Dwyer PJ, Tew KD, Hamilton TC, Ozols RF. Schröder CP, et al. Among authors: ozols rf. Cancer Invest. 1996;14(2):158-68. doi: 10.3109/07357909609018891. Cancer Invest. 1996. PMID: 8597901 Review. No abstract available.
Factoring outcomes in ovarian cancer.
Bookman MA, Ozols RF. Bookman MA, et al. Among authors: ozols rf. J Clin Oncol. 1996 Feb;14(2):325-7. doi: 10.1200/JCO.1996.14.2.325. J Clin Oncol. 1996. PMID: 8636738 No abstract available.
260 results